8-K: Evoke Pharma Appoints Greg Pyszcymuka to Board of Directors

Evoke Pharma appoints Greg Pyszcymuka to its Board of Directors, effective immediately, with an initial term expiring at the 2026 annual meeting.

Summary

• Evoke Pharma has appointed Greg Pyszcymuka to its Board of Directors, effective February 20, 2025.
• Mr. Pyszcymuka will serve as a Class I director with an initial term expiring at the company's 2026 annual meeting of stockholders.
• He will also serve on the Compensation Committee and the Nominating and Corporate Governance Committee.
• Mr. Pyszcymuka has served as the Chief Commercial Officer of Aytu Biopharma since January 2022.
• Prior to Aytu Biopharma, he held leadership roles at Neos Therapeutics, Aqua Pharmaceuticals, Iroko Pharmaceuticals, Zogenix, and Endo Pharmaceuticals.
• He holds a B.S. from Rutgers University and an M.B.A. from Argosy University.
• Mr. Pyszcymuka was granted options to purchase 5,833 shares of Evoke Pharma's common stock, vesting annually over three years.
• He will receive cash compensation for his board service in accordance with the company's non-employee director compensation program.
• Mr. Pyszcymuka has entered into the company's standard Indemnification Agreement.
• His appointment is pursuant to nominating rights granted in a letter agreement with Nantahala Capital Management, LLC, dated September 27, 2024.
• The Board has determined that Mr. Pyszcymuka is an independent director according to Nasdaq Capital Market listing requirements.

Sentiment

Score: 7

Explanation: The announcement is a routine corporate governance matter, indicating a stable and functioning company. The appointment of an experienced executive to the board is generally viewed positively.

Positives

• The appointment of Greg Pyszcymuka brings significant commercial experience to Evoke Pharma's Board, given his extensive background in the pharmaceutical industry.
• His experience at Aytu Biopharma, Neos Therapeutics, and other companies could provide valuable insights for Evoke Pharma's commercial strategy.
• The Board has determined that Mr. Pyszcymuka is an independent director, which supports good corporate governance.

Future Outlook

The document does not contain specific forward-looking statements regarding the company's financial performance or future prospects beyond the director's term.

Industry Context

This announcement reflects a common practice in the pharmaceutical industry where companies appoint experienced executives to their boards to provide strategic guidance and oversight. Greg Pyszcymuka's background in commercial operations and marketing aligns with Evoke Pharma's focus on commercializing its products.

Comparison to Industry Standards

• The appointment of independent directors and the structure of board committees are standard practices in publicly traded companies, aligning with Nasdaq's listing requirements and corporate governance best practices.
• Granting stock options to non-employee directors is a common form of compensation, similar to practices at companies like Amarin Corporation and Supernus Pharmaceuticals, to align their interests with those of shareholders.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders may view the appointment positively, as it brings additional expertise to the Board.
• Employees may see it as a sign of stability and growth for the company.

Key Dates

Keywords

Board of Directors, Evoke Pharma, Greg Pyszcymuka, Appointment, Director, Compensation Committee, Nantahala Capital Management, Corporate Governance